5% af de dasatinib- behandlede patienter, som havde normale baselineniveauer, oplevede grad 3 eller 4 forbigående hypokalcæmi på et tidspunkt under forløbet.
Approximately 5% of the dasatinib-treated patients who had normal baseline levels experienced grade 3 or 4 transient hypocalcemia at some time during the course of the study.